Sign In
Buy TARS
$58.76
+1.35 (+2.35%)
At Close: Jun 03, 2026
Tarsus to Participate in Upcoming Investor Conferences
04:30pm, Thursday, 28'th May 2026
IRVINE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:
Tarsus Q1 Review: Strong Earnings, But Wall Street Wanted A Guidance Raise
10:43am, Friday, 15'th May 2026
Tarsus Pharmaceuticals (TARS) is reiterated as a Strong Buy, with a 12-month price target of $95 per share amid sector-wide healthcare weakness. Xdemvy's Q1 sales more than doubled YoY, but unchanged
IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced a new partnership with John Cena to raise awareness of Demodex blepharitis, a common but of
Tarsus Pharmaceuticals, Inc. (TARS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
09:20pm, Tuesday, 12'th May 2026
Tarsus Pharmaceuticals, Inc. (TARS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Tarsus to Participate in Upcoming Investor Conferences
05:00pm, Thursday, 07'th May 2026
IRVINE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:
Tarsus Pharmaceuticals, Inc. (TARS) Q1 2026 Earnings Call Transcript
09:41pm, Wednesday, 06'th May 2026
Tarsus Pharmaceuticals, Inc. (TARS) Q1 2026 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Beats Revenue Estimates
07:31pm, Wednesday, 06'th May 2026
Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $0.64 per share a year ago.
Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements
04:05pm, Wednesday, 06'th May 2026
Generated first quarter XDEMVY ® net product sales of more than $145 million, an increase of more than 85% year-over-year Reaffirmed full-year 2026 guidance of $670-700 million of XDEMVY net product
Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
04:30pm, Wednesday, 29'th Apr 2026
IRVINE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m.
Calamos Advisors LLC Makes New $2.82 Million Investment in Tarsus Pharmaceuticals, Inc. $TARS
04:56am, Monday, 27'th Apr 2026
Calamos Advisors LLC purchased a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchan
Tarsus Pharmaceuticals: Marketing Spend Bears Fruit, Pipeline Progresses
01:44am, Tuesday, 14'th Apr 2026
Tarsus Pharmaceuticals has performed an aggressive marketing push for Xdemvy in Demodex blepharitis, with early signs of payoff seen, as sales now exceed SG&A expense. The company has appointed star b
Capricorn Fund Managers Ltd Decreases Position in Tarsus Pharmaceuticals, Inc. $TARS
04:45am, Monday, 06'th Apr 2026
Capricorn Fund Managers Ltd lessened its position in Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) by 90.8% during the undefined quarter, according to the company in its most recent Form 13F filing with
IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that the first participant has been dosed in the Phase 2 clinical trial (Calliope) evalua
Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade
01:06pm, Tuesday, 24'th Mar 2026
An executive at Tarsus Pharmaceuticals sold 12,274 shares for a transaction value of approximately $839,000, based on a weighted average price of $68.36 per share across three days ending March 19, 20
IRVINE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that a $15 million milestone payment due Tarsus has been achieved following regulatory ap
